Written and maintained by CASRAI Editorial Board
Last updated
Pharmaprojects is a global pharmaceutical pipeline and drug development intelligence database that tracks candidate therapeutics from early discovery and preclinical evaluation through clinical trials, regulatory review, and commercial launch. Operated by Citeline (a Norstella company), Pharmaprojects serves biopharmaceutical developers, contract research organizations (CROs), and life sciences investors for competitive landscape mapping, target mechanism saturation analysis, and business development and licensing (BD&L) due diligence. In contract research workflows, pipeline tracking directly informs clinical feasibility assessments alongside trial execution platforms like Trialtrove.
What Is Pharmaprojects?
Pharmaprojects is a specialized drug intelligence solution designed to monitor the global landscape of therapeutic development. Established in 1980 by Ian Morton at PJB Publications to track emerging pharmaceutical compounds, the platform developed under Informa Pharma Intelligence and was integrated into Norstella following the 2022 merger uniting Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group. Today, the platform operates as Pharmaprojects+, combining longitudinal pipeline records with artificial intelligence and comparative analytics.
Unlike open-access chemical repositories such as ChEMBL that prioritize molecular structures and in vitro assay affinities, Pharmaprojects focuses on the strategic, regulatory, and commercial progression of clinical candidates. It documents which corporate sponsors own or license each asset, what specific clinical indications are under active investigation, what regulatory designations have been granted (such as Fast Track or Orphan Drug designations), and whether development has advanced, stalled, or been discontinued.
The database plays a critical role in biopharmaceutical decision-making. Research and development teams use it to identify crowded biological targets, commercial teams use it to evaluate licensing candidates, and CRO leadership uses it to project market demand when planning service lines, such as comparing sponsor vs CRO operational responsibilities across specialized therapeutic areas.
Who Runs It and What It Covers
Pharmaprojects is maintained by Citeline, an enterprise life sciences information provider within Norstella. The database is curated by dedicated, therapeutically aligned industry analysts who continuously extract, cross-reference, and verify information from clinical trial registries, regulatory authority submissions (including the FDA, EMA, PMDA, and NMPA), scientific congress presentations, peer-reviewed journals, and corporate investor disclosures. Subscribers can also query analysts directly through an integrated “Ask the Analyst” service to clarify ambiguous pipeline shifts.
The database’s scope spans the full breadth of modern therapeutic modalities and development stages:
- Extensive Asset Inventory: Tracks more than 90,000 total candidate drugs historically, maintaining active records on approximately 20,000 therapeutic programs in progress across more than 160 countries.
- Full Lifecycle Coverage: Follows molecules from initial discovery and preclinical pharmacology through Phase I, Phase II, and Phase III clinical trials, pre-registration filing, market launch, and eventual patent expiration or discontinuation.
- Diverse Modalities: Captures traditional small-molecule synthetics alongside advanced modalities, including monoclonal antibodies, antibody-drug conjugates (ADCs), recombinant proteins, mRNA therapies, cell therapies (such as CAR-T), gene therapies, and oligonucleotide platforms.
- Historical Progression Snapshots: Maintains annual data snapshots dating back to 1995, enabling analysts to model historical phase transition probabilities, clinical attrition benchmarks, and shifting disease-area priorities over three decades.
How to Search and Use Pharmaprojects
Strategic planners, competitive intelligence specialists, and CRO feasibility directors interact with Pharmaprojects through a structured analytical workflow:
- Executing Natural Language Queries via Ella: Query candidate compounds, disease areas, or biological targets using plain-language prompts through “Ella,” the platform’s embedded AI assistant. Ella parses conversational queries, constructs validated multi-parameter searches, and presents structured summaries drawn directly from curated pipeline data.
- Applying Granular Taxonomic Filters: Filter the pipeline by standardized criteria, including therapeutic class, target organ system, biological mechanism of action (MoA), molecular target, or specific disease indication using standardized terminology.
- Segmenting by Development Phase and Geographic Territory: Narrow candidate lists by highest stage of active development—ranging from preclinical to approved—and specify target countries or regulatory jurisdictions to assess regional market competition.
- Benchmarking Competitor Portfolios with Company Compare: Utilize the “Company Compare” interface to benchmark two or more biopharmaceutical pipelines side by side, evaluating portfolio breadth, phase distribution, and therapeutic overlap to identify commercial threats or acquisition white spaces.
- Evaluating Comparable Assets with the Drug Similarity Tool: Use algorithmic similarity matching to identify chemical, biological, and mechanistic comparators. This feature extends beyond exact structural matching to find alternative molecules engaging the same biochemical pathway across different clinical indications.
- Interoperability with Clinical Execution Platforms: Seamlessly transition from drug discovery data to clinical operations by opening linked records in Trialtrove for study design parameters and consulting clinical trial site selection resources in Sitetrove.
- Automating Monitoring via Alerts and Cloud Integration: Establish automated email alerts for status shifts, orphan designations, or discontinuations, or ingest structured pipeline tables into internal enterprise data warehouses using REST APIs or native Snowflake data shares.
Strengths and Limits
Evaluating Pharmaprojects requires balancing its depth of intelligence against its commercial and structural limitations.
Strengths:
- Authoritative Expert Curation: Unlike automated web scrapers, data is verified by therapeutically aligned human analysts who validate corporate claims against regulatory filings and trial registries.
- Unrivaled Historical Depth: With continuous records dating back to 1980 and systematic annual snapshots since 1995, the database provides robust empirical data for clinical attrition and success-rate modeling.
- Systematic Attrition Tracking: The platform preserves comprehensive records of failed, stalled, and discontinued compounds (“fallen angels”), offering valuable intelligence for drug repositioning and safety retrospective studies.
- Connected Life Sciences Ecosystem: Integration across the Citeline product suite (Trialtrove for trial protocols, Sitetrove for investigators) provides a unified pathway from preclinical scouting to site activation.
Limits:
- Enterprise Subscription Costs: Access requires high-tier enterprise licensing, which places the tool out of reach for individual independent researchers, small laboratories, or budget-constrained academic departments.
- Reliance on Disclosed Intelligence: Because curation relies on regulatory filings, patents, and disclosures, covert early-stage discovery programs kept confidential by private biotechs cannot be captured until public disclosures occur.
- Analytical Complexity: Navigating complex multi-indication drugs with differing developmental phases across jurisdictions requires familiarity with pharmaceutical taxonomy and platform navigation.
Comparison of Drug Development Intelligence Databases
The following table compares Pharmaprojects with alternative drug pipeline databases, regulatory intelligence platforms, and molecular repositories:
| Platform | Primary Scope & Focus | Key Features & Delivery | Primary User Base | Operational Distinction |
|---|---|---|---|---|
| Pharmaprojects (Citeline) | Global drug pipeline intelligence and R&D asset tracking | Company Compare, Drug Similarity, Ella AI, Snowflake data shares | BD&L teams, R&D strategy, biopharma executives, CRO analysts | Deepest longitudinal pipeline tracking with dedicated clinical attrition records |
| Clarivate Cortellis | Integrated life sciences, regulatory, patent, and deal intelligence | Competitive intelligence, regulatory summaries, patent analytics | Regulatory affairs, corporate strategy, IP counsel, portfolio managers | Broader integration of patent claims and regulatory compliance documentation (see Cortellis guide) |
| Springer Nature AdisInsight | Scientifically evaluated drug pipelines, safety reports, and trials | Pharmacovigilance safety signals, curated trial outcome summaries | Academic medical centers, pharmacovigilance specialists, clinical evaluators | Stronger emphasis on post-marketing adverse event evaluations and published clinical summaries |
| GlobalData Healthcare | Macro market forecasting, epidemiology, and commercial landscape | Therapeutic market models, sales projections, KOL opinion reports | Commercial launch teams, equity research analysts, market access directors | Focuses on commercial revenue forecasting and epidemiological patient sizing |
| ChEMBL (EMBL-EBI) | Open-access bioactivity, binding affinity, and chemical repository | Free web query, open REST API, downloadable chemical databases | Computational chemists, academic researchers, structural biologists | Open-source molecular repository focused on in vitro pharmacology rather than corporate pipeline tracking |
Frequently Asked Questions
What is the difference between Pharmaprojects and Pharmaprojects+?
Pharmaprojects+ is the modernized, current generation of Citeline’s Pharmaprojects platform. It retains the complete historical and active pipeline data curated by Citeline analysts while introducing enhanced analytical features, including side-by-side Company Compare benchmarking, algorithmic Drug Similarity evaluation, and “Ella,” an embedded generative AI assistant for natural language querying.
How does Pharmaprojects track failed and discontinued drugs?
Pharmaprojects maintains dedicated tracking of terminated, suspended, or discontinued compounds rather than purging them from the system. Analysts categorize reasons for discontinuation—such as clinical safety issues, lack of efficacy, or strategic commercial reprioritization—allowing BD&L and discovery teams to assess safety lessons and identify repositioning candidates.
What is Ella in Pharmaprojects+?
Ella is the conversational AI assistant integrated directly into Pharmaprojects+. Users can ask natural language questions regarding drug mechanisms, competitor portfolios, or trial milestones. Ella translates these questions into validated search filters, queries the database, and returns structured, evidence-backed summaries with direct links to the underlying asset records.
Does Pharmaprojects integrate with Trialtrove?
Yes. Pharmaprojects is designed to interoperate natively with Trialtrove, Citeline’s clinical trials intelligence database. Within any candidate drug record in Pharmaprojects, users can click through to inspect ongoing and completed clinical trials, enrollment metrics, protocol designs, and primary endpoints in Trialtrove.
How can organizations export or integrate Pharmaprojects data into internal systems?
In addition to web application access, Citeline provides automated data delivery through REST APIs, scheduled SFTP transfers (in CSV or Parquet formats), and native cloud database shares via Snowflake, allowing enterprise data teams to blend pipeline metrics with proprietary internal discovery data.
Sources
- Citeline. “Pharmaprojects+: Pipeline Intelligence for Every Drug Development Decision.” citeline.com. Read November 7, 2026.
- Citeline. “Pharmaprojects Product Features and Analytical Workflows.” citeline.com. Read November 7, 2026.
- Norstella. “Connected Life Sciences Intelligence Solutions: Pharmaprojects & Trialtrove.” norstella.com. Read November 7, 2026.
- European Molecular Biology Laboratory. “ChEMBL: Open Bioactivity Database for Drug Discovery.” ebi.ac.uk. Read November 7, 2026.
